BioMedNewsBreaks

FridayMay 14, 2021 1:35 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Focuses ‘Covid-ID Lab’ Commercialization Strategy Initially on German Market

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its entry into the agreement with a full-fledged German pharmaceutical wholesaler and service provider. Under the agreement, the German partner will distribute, store and deliver Covid-ID Lab test kits to XPhyto’s customers in line with product specifications and relevant logistical and regulatory requirements in Germany. A recent article quotes XPhyto CEO and Director Hugh Rogers, who noted that the company had secured a strong partner…

Continue Reading

FridayMay 14, 2021 12:38 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Collaborating to Potentially Uncover Innovative New Treatment Options

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, recently began a collaboration with JelikaLite in a clinical trial. The clinical trial, which has 30 participants from two New York City locations, is designed to potentially uncover new treatment options to reduce autism symptoms in children. “JelikaLite was launched by medical researchers and practitioners specializing in psychology, neurology and phototherapy. The company has developed an innovative solution to potentially reduce autism symptoms and is developing a home-based system that combines a therapeutic wearable device called Cognilum(TM) with an AI-personalized platform. . . Cognilum delivers treatments…

Continue Reading

FridayMay 14, 2021 10:57 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2021 Results, Provides Clinical Update and Business Outlook

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided a clinical update and business outlook and released its financial results for the quarter ended March 31, 2021. "2021 is poised to be an exciting year for the company. Throughout the first quarter, we have made continued development and regulatory progress on all fronts and are committed to driving our novel treatments forward as expeditiously as possible with the primary focus on our Berubicin program to improve patient outcomes for GBM," said…

Continue Reading

FridayMay 14, 2021 10:54 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2021 Financial, Corporate Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial and corporate results for the first quarter of 2021, the period ended March 31, 2021. In the report, PCSA noted that its clinical drug pipeline is funded and targeting major milestones throughout this year. Corporate highlights for the company included the selection of five clinical sites around the United States for the upcoming phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of PCS499 in treating patients who…

Continue Reading

FridayMay 14, 2021 9:36 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in “Forbes” Article

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was featured in a recent “Forbes” article touting six keys to leadership growth. In the article, McKee shared valuable insight into the most effective ways that leaders can grow and develop. The behaviors McKee encouraged include staying curious and stepping outside of your comfort zone as well as not waiting for experiences and making experiences as you go. McKee also urged potential leaders to never stop learning and, in fact, noted that they could learn from every experience. McKee also encouraged leaders to not be afraid of breaking with convention.…

Continue Reading

ThursdayMay 13, 2021 11:49 am

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) RYAH Medtech Expands Business Development Team

RYAH Group’s (CSE: RYAH) wholly owned subsidiary, RYAH Medtech Inc., has welcomed four new members to its business development team, namely Steven Schultz, Warren Thompson, Mitchell Zimmer, and Andrea Ferrari. According to the update, the newly added experts bring extensive experience and expertise in the medical and pharmaceutical industry. The team will focus on expanding RYAH’s presence in multiple verticals within the North America plant-based and nutraceutical markets, including participation in clinical trials for the company’s connected devices and custom software solutions in data analytics. “We are thrilled to announce these new appointments. This team has deep acumen in the medical…

Continue Reading

ThursdayMay 13, 2021 10:26 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Releases Business, Drug-Development Status

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, released an update on its 2021 drug formulation programs, noting that the programs are advancing on schedule and expanding in scope. The company’s Rotigotine transdermal human pilot study was successfully completed in March and the program now advancing to a pivotal study stage; the pilot study evaluated the use of the Rotigotine transdermal patch in the treatment for Parkinson's disease. In addition, the update noted that XPhyto had purchased land in Germany for the construction of its commercial drug manufacturing facility in…

Continue Reading

WednesdayMay 12, 2021 12:48 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Poised for Opportunity in Burgeoning Global Health Products Sector

Healthy Extracts (OTCQB: HYEX) is well-positioned to capitalize further on the rapidly growing health products market, which has already positively impacted the company. “The increasing interest, which has led to more demand for the products, has positively impacted HYEX, as evidenced by the company’s improved revenue from $748,377 in 2019 to $1,276,559 in 2020, representing a 71% jump,” reports a recent article. Healthy Extracts wholly owns two subsidiaries — Ultimate Brain Nutrients (“UBN”) and BergaMet North America. The global brain health supplements market, UBN’s domain, “is projected to reach $13.38 billion by 2028, marking a CAGR of 8.0% from 2021…

Continue Reading

TuesdayMay 11, 2021 11:37 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Q2 Virtual Investor Summit

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO John Climaco will present at the Q2 Virtual Investor Summit at 12:30 p.m. ET on Tuesday, May 18. In addition to the presentation, CNS management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. Interested parties should visit https://ibn.fm/sfnYa for more information and to register for the conference. A video webcast will be accessible on…

Continue Reading

TuesdayMay 11, 2021 11:26 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Announces Sales Team Expansion

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced the hiring of four additional sales representatives, including three for the veterinary market and one for the contract drug manufacturing market. “We are excited to have recruited very talented and experienced sales representatives from some of the biggest names in veterinary health care,” said Dr. Jack Regan, LexaGene’s CEO and founder. “Our new sales representatives have universally expressed optimism about selling LexaGene’s technology into veterinary hospitals, and the same is true for our sales representative targeting contract drug manufacturing organizations.…

Continue Reading